Aerosol therapy through high flow nasal cannula in pediatric patients

ABSTRACT Introduction: High flow nasal cannula (HFNC) is increasingly used in pediatric patients suffering from respiratory failure. In some disease processes, patients may also benefit from aerosol therapy. Therefore, the use of HFNC to deliver aerosolized medications is a convenient and attractive option. Areas covered: This review aims to appraise available evidence concerning the efficiency of aerosol nebulized therapy delivery using HFNC in pediatric patients. Expert commentary: Delivery of aerosol particles is a very complex process and depends on the use of oxygen vs. heliox, nebulizer type and position within the HFNC circuit, patient’s breathing effort and pattern, and more importantly cannula size and flow rates. Current in vitro evidence suggests the amount of aerosol delivery is likely to be very low at high flows. Clinical studies are limited in pediatric patients and given the limited clinical data, it is not possible to make recommendations for or against aerosol delivery through HFNC for pediatric patients.

[1]  Z. Memish,et al.  Burkholderia cepacia complex outbreaks among non-cystic fibrosis patients in the intensive care units: A review of adult and pediatric literature. , 2018, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

[2]  Arzu Ari,et al.  Aerosol Delivery Through Adult High Flow Nasal Cannula With Heliox and Oxygen , 2017, Respiratory Care.

[3]  A. Berlinski.  Pediatric Aerosol Therapy , 2017, Respiratory Care.

[4]  Ronan Mac Loughlin,et al.  Nasal high flow nebulization in infants and toddlers: An in vitro and in vivo scintigraphic study , 2017, Pediatric pulmonology.

[5]  A. Decaen,et al.  The Clinical Impact of Heated Humidified High-Flow Nasal Cannula on Pediatric Respiratory Distress , 2017, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[6]  G. Cambonie,et al.  High flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory management of acute viral bronchiolitis in young infants: a multicenter randomized controlled trial (TRAMONTANE study) , 2017, Intensive Care Medicine.

[7]  R. Mink,et al.  983: CONTINUOUS ALBUTEROL DELIVERY VIA HIGH-FLOW NASAL CANNULA VERSUS AEROSOL MASK IN STATUS ASTHMATICUS , 2016, Critical care medicine.

[8]  K. Øymar,et al.  High flow nasal cannula in children: a literature review , 2016, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

[9]  G. van Amerongen,et al.  Optimization and Dose Estimation of Aerosol Delivery to Non-Human Primates. , 2016, Journal of aerosol medicine and pulmonary drug delivery.

[10]  D. Hess,et al.  High-flow oxygen therapy and other inhaled therapies in intensive care units , 2016, The Lancet.

[11]  P. Diot,et al.  Aerosol Therapy in Adults Receiving High Flow Nasal Cannula Oxygen Therapy. , 2016, Journal of aerosol medicine and pulmonary drug delivery.

[12]  J. Whitty,et al.  Early high flow nasal cannula therapy in bronchiolitis, a prospective randomised control trial (protocol): A Paediatric Acute Respiratory Intervention Study (PARIS) , 2015, BMC Pediatrics.

[13]  Arzu Ari,et al.  Comparison of HFNC, bubble CPAP and SiPAP on aerosol delivery in neonates: An in‐vitro study , 2015, Pediatric pulmonology.

[14]  Jesse B. Hall,et al.  High-Flow Nasal Cannula and Aerosolized β Agonists for Rescue Therapy in Children With Bronchiolitis: A Case Series , 2015, Respiratory Care.

[15]  Jinxiang Xi,et al.  In Vitro Evaluation of Aerosols Delivered via the Nasal Route , 2015, Respiratory Care.

[16]  L. Brochard,et al.  High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. , 2015, The New England journal of medicine.

[17]  D. Hess.  Aerosol Therapy During Noninvasive Ventilation or High-Flow Nasal Cannula , 2015, Respiratory Care.

[18]  Robert M Diblasi,et al.  Clinical Controversies in Aerosol Therapy for Infants and Children , 2015, Respiratory Care.

[19]  M. Newhouse,et al.  Nasal versus oral aerosol delivery to the “lungs” in infants and toddlers , 2015, Pediatric pulmonology.

[20]  Arzu Ari,et al.  Performance Comparisons of Jet and Mesh Nebulizers Using Different Interfaces in Simulated Spontaneously Breathing Adults and Children. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[21]  M. Hindle,et al.  Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[22]  Dan Raviv,et al.  Design of aerosol face masks for children using computerized 3D face analysis. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[23]  J. Fleming,et al.  Using helium-oxygen to improve regional deposition of inhaled particles: mechanical principles. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[24]  F. Bogossian,et al.  High-flow nasal cannula therapy for respiratory support in children. , 2014, The Cochrane database of systematic reviews.

[25]  L. Schlapbach,et al.  High-flow nasal cannula (HFNC) support in interhospital transport of critically ill children , 2014, Intensive Care Medicine.

[26]  Jinxiang Xi,et al.  Growth of Nasal and Laryngeal Airways in Children: Implications in Breathing and Inhaled Aerosol Dynamics , 2014, Respiratory Care.

[27]  J. Walters,et al.  High-flow nasal cannula therapy for infants with bronchiolitis. , 2014, The Cochrane database of systematic reviews.

[28]  R. Khemani,et al.  Effort of Breathing in Children Receiving High-Flow Nasal Cannula , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[29]  Arzu Ari,et al.  Aerosol therapy in children: challenges and solutions , 2013, Expert review of respiratory medicine.

[30]  J. Hertzog,et al.  Influences of Cannula Size and Flow Rate on Aerosol Drug Delivery Through the Vapotherm Humidified High-Flow Nasal Cannula System , 2013, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[31]  I. Cheifetz,et al.  Use of high flow nasal cannula in critically ill infants, children, and adults: a critical review of the literature , 2013, Intensive Care Medicine.

[32]  J. Fink.  Delivery of inhaled drugs for infants and small children: a commentary on present and future needs. , 2012, Clinical therapeutics.

[33]  M. Newhouse,et al.  Deposition of small particles in the developing lung. , 2012, Paediatric respiratory reviews.

[34]  M. Newhouse,et al.  Nasal aerosol delivery to the lower respiratory tract may be superior to oral delivery in infants/toddlers , 2012 .

[35]  Ruben D. Restrepo,et al.  Aerosol Delivery Device Selection for Spontaneously Breathing Patients: 2012 , 2012, Respiratory Care.

[36]  Arzu Ari,et al.  In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula , 2011, Pediatric pulmonology.

[37]  Arzu Ari,et al.  Guidelines for aerosol devices in infants, children and adults: which to choose, why and how to achieve effective aerosol therapy , 2011, Expert review of respiratory medicine.

[38]  R. Williams,et al.  Influence of particle size on regional lung deposition--what evidence is there? , 2011, International journal of pharmaceutics.

[39]  J. Carcillo,et al.  Aerosol delivery through nasal cannulas: an in vitro study. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[40]  G Kim Prisk,et al.  Aerosol deposition in the human lung periphery is increased by reduced-density gas breathing. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[41]  J. Wildhaber,et al.  Facemasks and aerosol delivery in vivo. , 2007, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[42]  O. Usmani,et al.  Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .

[43]  C. Cole,et al.  Special problems in aerosol delivery: neonatal and pediatric considerations. , 2000, Respiratory care.

[44]  R. Iles,et al.  Crying significantly reduces absorption of aerosolised drug in infants , 1999, Archives of disease in childhood.

[45]  J. Wildhaber,et al.  Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. , 1999, The Journal of pediatrics.

[46]  Pieter Zanen,et al.  The optimal particle size for parasympathicolytic aerosols in mild asthmatics , 1995 .

[47]  P Camner,et al.  Deposition in asthmatics of particles inhaled in air or in helium-oxygen. , 1993, The American review of respiratory disease.

[48]  M. Silverman,et al.  Delivery of therapeutic aerosols to intubated babies. , 1992, Archives of disease in childhood.

[49]  S. Spiro,et al.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. , 1990, Thorax.

[50]  J. Heyder,et al.  Deposition pattern of droplets from medical nebulizers in the human respiratory tract. , 1983, Bulletin europeen de physiopathologie respiratoire.

[51]  United States NATIONAL INSTITUTES OF HEALTH , 1980, The Lancet.

[52]  W Stahlhofen,et al.  Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. , 1980, American Industrial Hygiene Association journal.

[53]  J. Walters,et al.  High-flow nasal cannula therapy for infants with bronchiolitis (Protocol) , 2012 .

[54]  T. Shaffer,et al.  Nasal cannula, CPAP, and high-flow nasal cannula: effect of flow on temperature, humidity, pressure, and resistance. , 2011, Biomedical instrumentation & technology.

[55]  S. Devadason,et al.  Age-associated factors influencing the efficacy of various forms of aerosol therapy. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[56]  M. Svartengren,et al.  Human lung deposition of particles suspended in air or in helium/oxygen mixture. , 1989, Experimental lung research.

[57]  J. Heyder,et al.  Deposition of particles in the human respiratory tract in the size range 0.005–15 μm , 1986 .